ATAI ATAI LIFE SCIENCES BV

AtaiBeckley To Participate in Upcoming Investor Conferences

AtaiBeckley To Participate in Upcoming Investor Conferences

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March.

TD Cowen 46th Annual Health Care Conference

  • Format: Fireside chat, Wednesday, March 4, from 11:50am – 12:20pm EST and one-on-one meetings
  • Location: Boston, Massachusetts



Jefferies 2026 Biotech on the Beach

  • Format: One-on-one meetings only, Tuesday, March 10
  • Location: Miami, Florida



Leerink Global Healthcare Conference

  • Format: Fireside chat, Wednesday, March 11, from 8:00am – 8:30am EST and one-on-one meetings
  • Location: Miami, Florida



Live webcasts of the fireside chats will be available on the investor section of the AtaiBeckley website, under . The archived webcasts will be available for at least 30 days after the event.

About AtaiBeckley Inc.

AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on and on .

Investor and Media Relations

Investors:

Jason Awe, PhD

VP, Investor Relations

Media:

Charlotte Chorley

Associate Director, Communications



EN
17/02/2026

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in ...

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs 66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85: 83% (5/6) (10 mg) and 66.7% (4/6) (12 mg)BPL-003 received FDA Breakthrough Therapy Designation in October 2025Phase 3 initiation on track for Q2 2026 NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckle...

April 8, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Add...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fundExpands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500®Continues a series of index inclusions acr...

March 24, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treat...

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study () evaluating BPL-003 (mebu...

March 17, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Succ...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studiesCommercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflowsContinued pipeline progress, including positive Phase 2a results for ...

March 10, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Result...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measuresCash run...

March 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch